Open-label study of olanzapine in children with pervasive developmental disorder

Journal of Clinical Psychopharmacology

Volumn 22, Issue 5, 2002, Pages 455-460

  Kemner, Chantal ^a   Willemsen Swinkels, Sophie H N ^a   De Jonge, Maretha ^a   Tuynman Qua, Hanneke ^a   Van Engeland, Herman ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE;

ADOLESCENT; AKATHISIA; APPETITE DISORDER; ARTICLE; AUTISM; CHILD; CHILD BEHAVIOR; CLINICAL ARTICLE; DEVELOPMENTAL DISORDER; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HUMAN; HYPERACTIVITY; HYPERSALIVATION; IRRITABILITY; MALE; NERVOUSNESS; PRIORITY JOURNAL; PSYCHOMETRY; RATING SCALE; SOMNOLENCE; TREMOR; VERBAL COMMUNICATION; WEIGHT GAIN;

EID: 0036785079     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200210000-00003     Document Type: Article

References (14)

1. Borison RL. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 1995;15 [Suppl 1]:24S-29S.
2. Buchanan RW. Clozapine: efficacy and safety. Schizophr Bull 1995 ;21:579-91.
3. Tollefson GD, Kuntz AJ. Review of recent clinical studies with olanzapine. Br J Psychiatry Suppl 1999;37:30-5.
4. Potenza MN, Holmes JP, Kanes SJ, et al. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999;19:37-44.
5. Krishnamoorthy J, King BH. Open-label olanzapine treatment in five preadolescent children. J Child Adolesc Psychopharmacol 1998;8:107-13.
6. Demb HB, Roychoudhury K. Comments on "Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study." J Clin Psychopharmacol 2000;20:580-1.
7. Potenza MN, McDougle CJ. Reply to comments on "Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study." J Clin Psychopharmacol 2001;21:246-7.
8. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994;24:659-85.
9. NIMH. Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull 1985; 21:714-1124.
10. Lord C, Risi S, Lambrecht L, et al. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord 2000;30:205-23.
11. Noldus LP, Trienes RJ, Hendriksen AH, et al. The Observer Video-Pro: new software for the collection, management, and presentation of time-structured data from videotapes and digital media files. Behav Res Methods Instrum Comput 2000;32:197-206.
12. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-6.
13. Ashbridge E, Walsh V, Cowey A. Temporal aspects of visual search studied by transcranial magnetic stimulation. Neuropsychologia 1997;35:1121-31.
14. McDougle CJ, Holmes JP, Carlson DC, et al. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 1998;55:633-41.